Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Pathogenesis of IBD

Free Access

Mechanisms and Functional Implications of Intestinal Barrier Defects

Shen L. · Su L. · Turner J.R.

Author affiliations

Department of Pathology, The University of Chicago, Chicago, Ill., USA

Corresponding Author

Prof. Dr. Jerrold R. Turner, MD, PhD

The University of Chicago, 5841 South Maryland, MC 1089

Chicago, IL 60637 (USA)

Tel. +1 773 702 2433, Fax +1 773 834 5159

E-Mail jturner@bsd.uchicago.edu

Related Articles for ""

Dig Dis 2009;27:443–449

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Abstract

Intestinal epithelial barrier defects, or increased paracellular permeability, were first reported in patients with Crohn’s disease (CD) over 25 years ago. Although increased permeability may herald relapse to active disease, suggesting that impaired barrier function may contribute to progression, limited understanding of the mechanisms that create barrier defects in CD has made it impossible to determine whether increased permeability is a cause or effect of disease. It is now clear that inflammatory cytokines trigger intestinal barrier defects acutely, by cytoskeletal contraction, or chronically, via modulation of tight junction protein expression. Both mechanisms cause barrier dysfunction, but their effects on paracellular size and charge selectivity differ. The clinical ramifications of this distinction are not yet clear. Recent data using in vivo models demonstrate that cytoskeletally mediated barrier dysfunction is sufficient to activate innate and adaptive components of mucosal immunity. Consistent with the presence of increased permeability in some healthy first-degree relatives of CD patients, these barrier defects are insufficient to cause disease in the absence of other stimuli. However, cytoskeletally mediated barrier defects are sufficient to accelerate onset and increase severity of experimental inflammatory bowel disease. Thus, inflammatory cytokines can cause barrier defects and, conversely, barrier defects can activate the mucosal immune system. This raises the possibility that restoration of barrier function may be therapeutic in CD. Consistent with this hypothesis, emerging data indicate that inhibition of cytoskeletally mediated barrier dysfunction may be able to prevent disease progression. Barrier restoration may, therefore, represent a non-immunosuppressive approach to achieving or maintaining disease remission.

© 2009 S. Karger AG, Basel


References

  1. Turner JR, Madara JL: Epithelia: biological principles of organization; in Yamada T, Alpers DH, Kalloo AN, Kaplowitz N, Owyang C, Powell DW (eds): Textbook of Gastroenterology, ed 5. New York, Blackwell Publishing, 2009, pp 169–186.
  2. Machen TE, Erlij D, Wooding FB: Permeable junctional complexes. The movement of lanthanum across rabbit gallbladder and intestine. J Cell Biol 1972;54:302–312.
  3. Claude P, Goodenough DA: Fracture faces of zonulae occludentes from ‘tight’ and ‘leaky’ epithelia. J Cell Biol 1973;58:390–400.
  4. Furuse M, Furuse K, Sasaki H, Tsukita S: Conversion of zonulae occludentes from tight to leaky strand type by introducing claudin-2 into Madin-Darby canine kidney I cells. J Cell Biol 2001;153:263–272.
  5. Amasheh S, Meiri N, Gitter AH, Schoneberg T, Mankertz J, Schulzke JD, et al: Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells. J Cell Sci 2002;115:4969–4976.
  6. Fihn BM, Sjoqvist A, Jodal M: Permeability of the rat small intestinal epithelium along the villus-crypt axis: effects of glucose transport. Gastroenterology 2000;119:1029–1036.
  7. Marcial MA, Carlson SL, Madara JL: Partitioning of paracellular conductance along the ileal crypt-villus axis: a hypothesis based on structural analysis with detailed consideration of tight junction structure-function relationships. J Membr Biol 1984;80:59–70.
  8. Madara JL, Pappenheimer JR: Structural basis for physiological regulation of paracellular pathways in intestinal epithelia. J Membr Biol 1987;100:149–164.
  9. Turner JR, Rill BK, Carlson SL, Carnes D, Kerner R, Mrsny RJ, et al: Physiological regulation of epithelial tight junctions is associated with myosin light-chain phosphorylation. Am J Physiol 1997;273:C1378– C1385.
  10. Fine KD, Santa Ana CA, Porter JL, Fordtran JS: Effect of D-glucose on intestinal permeability and its passive absorption in human small intestine in vivo. Gastroenterology 1993;105:1117–1125.
  11. Madara JL: Sodium-glucose cotransport and epithelial permeability. Gastroenterology 1994;107:319–320.
  12. Turner JR, Madara JL: Physiological regulation of intestinal epithelial tight junctions as a consequence of Na+-coupled nutrient transport. Gastroenterology 1995;109:1391–1396.
  13. Sadowski DC, Meddings JB: Luminal nutrients alter tight-junction permeability in the rat jejunum: an in vivo perfusion model. Can J Physiol Pharmacol 1993;71:835–839.
  14. Turner JR, Cohen DE, Mrsny RJ, Madara JL: Noninvasive in vivo analysis of human small intestinal paracellular absorption: regulation by Na+-glucose cotransport. Dig Dis Sci 2000;45:2122–2126.
  15. Pappenheimer JR: Paracellular intestinal absorption of glucose, creatinine, and mannitol in normal animals: relation to body size. Am J Physiol 1990;259:G290–G299.
  16. Pappenheimer JR: Physiological regulation of transepithelial impedance in the intestinal mucosa of rats and hamsters. J Membr Biol 1987;100:137–148.
  17. Pearson AD, Eastham EJ, Laker MF, Craft AW, Nelson R: Intestinal permeability in children with Crohn’s disease and coeliac disease. Br Med J (Clin Res Ed) 1982;285: 20–21.
  18. Ukabam SO, Clamp JR, Cooper BT: Abnormal small intestinal permeability to sugars in patients with Crohn’s disease of the terminal ileum and colon. Digestion 1983;27:70–74.
  19. Marin ML, Greenstein AJ, Geller SA, Gordon RE, Aufses AH Jr: A freeze fracture study of Crohn’s disease of the terminal ileum: changes in epithelial tight junction organization. Am J Gastroenterol 1983;78:537–547.
  20. Marin ML, Geller SA, Greenstein AJ, Marin RH, Gordon RE, Aufses AH Jr: Ultrastructural pathology of Crohn’s disease: correlated transmission electron microscopy, scanning electron microscopy, and freeze fracture studies. Am J Gastroenterol 1983;78:355–364.
  21. Hollander D, Vadheim CM, Brettholz E, Petersen GM, Delahunty T, Rotter JI: Increased intestinal permeability in patients with Crohn’s disease and their relatives. A possible etiologic factor. Ann Intern Med 1986;105:883–885.
  22. Katz KD, Hollander D, Vadheim CM, McElree C, Delahunty T, Dadufalza VD, et al: Intestinal permeability in patients with Crohn’s disease and their healthy relatives. Gastroenterol 1989;97:927–931.
  23. Hollander D: Is Crohn’s a tight junction disease? Gut 1989;21:315–319.
  24. Hollander D: Permeability in Crohn’s disease: altered barrier functions in healthy relatives? Gastroenterology 1993;104:1848–1851.
  25. Buhner S, Buning C, Genschel J, Kling K, Herrmann D, Dignass A, et al: Genetic basis for increased intestinal permeability in families with Crohn’s disease: role of CARD15 3020insC mutation? Gut 2006;55:342–347.
  26. Irvine EJ, Marshall JK: Increased intestinal permeability precedes the onset of Crohn’s disease in a subject with familial risk. Gastroenterology 2000;119:1740–1744.
  27. Wyatt J, Vogelsang H, Hubl W, Waldhoer T, Lochs H: Intestinal permeability and the prediction of relapse in Crohn’s disease. Lancet 1993;341:1437–1439.
  28. D’Inca R, Di Leo V, Corrao G, Martines D, D’Odorico A, Mestriner C, et al: Intestinal permeability test as a predictor of clinical course in Crohn’s disease. Am J Gastroenterol 1999;94:2956–2960.
  29. Arnott ID, Kingstone K, Ghosh S: Abnormal intestinal permeability predicts relapse in inactive Crohn’s disease. Scand J Gastroenterol 2000;35:1163–1169.
  30. Bitton A, Dobkin P, Edwardes MD, Sewitch M, Meddings J, Rawal S, et al: Predicting relapse in Crohn’s disease: a biopsychosocial model. Gut 2008;57:1386–1392.
  31. Meddings JB, Swain MG: Environmental stress-induced gastrointestinal permeability is mediated by endogenous glucocorticoids in the rat. Gastroenterology 2000;119:1019–1028.
  32. Schmitz H, Barmeyer C, Fromm M, Runkel N, Foss HD, Bentzel CJ, et al: Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology 1999;116:301–309.
  33. Meddings JB, Gibbons I: Discrimination of site-specific alterations in gastrointestinal permeability in the rat. Gastroenterology 1998;114:83–92.
  34. Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, et al: Interleukin-13 is the key effector Th2 cytokine in ul- cerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005;129:550–564.
  35. Prasad S, Mingrino R, Kaukinen K, Hayes KL, Powell RM, MacDonald TT, et al: Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab Invest 2005;85:1139–1162.
  36. Van Itallie CM, Holmes J, Bridges A, Gookin JL, Coccaro MR, Proctor W, et al: The density of small tight junction pores varies among cell types and is increased by expression of claudin-2. J Cell Sci 2008;121:298–305.
  37. Zeissig S, Burgel N, Gunzel D, Richter J, Mankertz J, Wahnschaffe U, et al: Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn’s disease. Gut 2007;56:61–72.
  38. Baert FJ, D’Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, et al: Tumor necrosis factor-α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis. Gastroenterology 1999;116:22–28.
  39. D’Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, et al: Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology 1999;116:1029–1034.
  40. Rutgeerts P, Sandborn WJ, Feagan BG, Rei-nisch W, Olson A, Johanns J, et al: Inflixi-mab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–2476.
  41. Suenaert P, Bulteel V, Lemmens L, Noman M, Geypens B, Van Assche G, et al: Anti-tumor necrosis factor treatment restores the gut barrier in Crohn’s disease. Am J Gastroenterol 2002;97:2000–2004.
  42. Taylor CT, Dzus AL, Colgan SP: Autocrine regulation of epithelial permeability by hypoxia: role for polarized release of tumor necrosis factor-α. Gastroenterology 1998;114:657–668.
  43. Wang F, Graham WV, Wang Y, Witkowski ED, Schwarz BT, Turner JR: Interferon-γ and tumor necrosis factor-α synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am J Pathol 2005;166:409–419.
  44. Zolotarevsky Y, Hecht G, Koutsouris A, Gonzalez DE, Quan C, Tom J, et al: A membrane-permeant peptide that inhibits MLC kinase restores barrier function in in vitro models of intestinal disease. Gastroenterology 2002;123:163–172.
  45. Ma TY, Boivin MA, Ye D, Pedram A, Said HM: Mechanism of TNF-α modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. Am J Physiol 2005;288:G422–G430.
  46. Graham WV, Wang F, Clayburgh DR, Cheng JX, Yoon B, Wang Y, et al: Tumor necrosis factor-induced long myosin light chain kinase transcription is regulated by differentiation-dependent signaling events. Characterization of the human long myosin light chain kinase promoter. J Biol Chem 2006;281:26205–26215.
  47. Blair SA, Kane SV, Clayburgh DR, Turner JR: Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. Lab Invest 2006;86:191–201.
  48. Musch MW, Clarke LL, Mamah D, Gawenis LR, Zhang Z, Ellsworth W, et al: T-cell activation causes diarrhea by increasing intestinal permeability and inhibiting epithelial Na+,K+-ATPase. J Clin Invest 2002;110: 1739–1747.
  49. Clayburgh DR, Barrett TA, Tang Y, Meddings JB, Van Eldik LJ, Watterson DM, et al: Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T-cell activation-induced diarrhea in vivo. J Clin Invest 2005;115:2702–2715.
  50. Clayburgh DR, Musch MW, Leitges M, Fu YX, Turner JR: Coordinated epithelial NHE3 inhibition and barrier dysfunction are required for TNF-mediated diarrhea in vivo. J Clin Invest 2006;116:2682–2694.
  51. Ferran C, Dy M, Merite S, Sheehan K, Schreiber R, Leboulenger F, et al: Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids. Transplantation 1990;50:642–648.
  52. Ferran C, Sheehan K, Dy M, Schreiber R, Merite S, Landais P, et al: Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur J Immunol 1990;20:509–515.
  53. Abramowicz D, Crusiaux A, Goldman M: Anaphylactic shock after retreatment with OKT3 monoclonal antibody. N Engl J Med 1992;327:736.
  54. Stull JT: Myosin minireview series. J Biol Chem 1996;271:15849.
  55. Kamm KE, Stull JT: Dedicated myosin light chain kinases with diverse cellular functions. J Biol Chem 2001;276:4527–4530.
  56. Turner JR: Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am J Pathol 2006;169:1901–1909.
  57. Shen L, Black ED, Witkowski ED, Lencer WI, Guerriero V, Schneeberger EE, et al: Myosin light chain phosphorylation regulates barrier function by remodeling tight junction structure. J Cell Sci 2006;119:2095–2106.
  58. Su L, Shen L, Clayburgh DR, Nalle SC, Sullivan EA, Meddings JB, et al: Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology 2009;136:551–563.
  59. Ostanin DV, Bao J, Koboziev I, Gray L, Robinson-Jackson SA, Kosloski-Davidson M, et al: T-cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade. Am J Physiol 2009;296:G135–G146.
  60. Te Velde AA, de Kort F, Sterrenburg E, Pronk I, ten Kate FJ, Hommes DW, et al: Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease. Inflamm Bowel Dis 2007;13:325–330.
  61. Powrie F, Correa-Oliveira R, Mauze S, Coffman RL: Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 1994;179:589–600.
  62. Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL: Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol 1993;5:1461–1471.

Article / Publication Details

First-Page Preview
Abstract of Pathogenesis of IBD

Published online: November 04, 2009
Issue release date: November 2009

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0

ISSN: 0257-2753 (Print)
eISSN: 1421-9875 (Online)

For additional information: https://www.karger.com/DDI


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.